Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study

• Published in: British journal of haematology 2016-01, Vol.172 (1), p.89-96
• Main Authors: Muchtar, Eli, Gatt, Moshe E., Rouvio, Ory, Ganzel, Chezi, Chubar, Evgeni, Suriu, Celia, Tadmor, Tamar, Shevetz, Olga, Lavi, Noa, Shochat, Tzippy, Cohen, Yael C., Avivi, Irit, Raanani, Pia, Magen, Hila
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; carfilzomib; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma - drug therapy; Multiple Myeloma - pathology; myeloma; Neoplasm Staging; Oligopeptides - administration & dosage; Oligopeptides - adverse effects; Oligopeptides - therapeutic use; Proteasome Inhibitors - administration & dosage; Proteasome Inhibitors - adverse effects; Proteasome Inhibitors - therapeutic use; Recurrence; relapse; resistance; Retrospective Studies; Salvage Therapy - adverse effects; Salvage Therapy - methods; Survival Analysis; Time Factors; Treatment Outcome
• ISSN: 0007-1048; 1365-2141
• DOI: 10.1111/bjh.13799

Summary Carfilzomib has been established in previous years as a treatment for patients with relapsed and/or refractory multiple myeloma (RR‐MM). A retrospective multicentre study to evaluate the clinical use of carfilzomib for RR‐MM outside of a clinical trial setting was conducted by our group. One hundred and thirty‐five patients were included. All patients had been previously exposed to bortezomib and 93% had also been treated with lenalidomide. The vast majority of patients received carfilzomib as part of a two‐ or three‐drug combination. The overall response rate was 47·2%. Multivariate analysis revealed bortezomib resistance, lenalidomide resistance and albumin